FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004037338> ?p ?o ?g. }

• W2004037338 endingPage "3216" @default.
• W2004037338 startingPage "3208" @default.
• W2004037338 abstract "Activation of androgen receptor (AR) may have a role in the development of castration-resistant prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in castrated animals. However, the upstream signals that activate these kinases and lead to AR activation are incompletely characterized. In this study, we investigated AR phosphorylation in response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6. Small interfering RNA-mediated knockdown of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation, whereas Src mediates Tyr-534 phosphorylation induced by EGF, IL-6 and bombesin. Dasatinib, a Src inhibitor, blocked EGF-induced Tyr-534 phosphorylation. In addition, we showed that dasatinib also inhibited Ack1 kinase. Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib may exert antitumor activity in prostate cancer through inhibition of Ack1." @default.
• W2004037338 created "2016-06-24" @default.
• W2004037338 creator A5009183121 @default.
• W2004037338 creator A5009574665 @default.
• W2004037338 creator A5011907185 @default.
• W2004037338 creator A5039624947 @default.
• W2004037338 creator A5049715475 @default.
• W2004037338 creator A5089350105 @default.
• W2004037338 date "2010-04-12" @default.
• W2004037338 modified "2023-10-16" @default.
• W2004037338 title "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases" @default.
• W2004037338 cites W1965674043 @default.
• W2004037338 cites W1969241521 @default.
• W2004037338 cites W1975189002 @default.
• W2004037338 cites W1976784043 @default.
• W2004037338 cites W1983225862 @default.
• W2004037338 cites W1986276126 @default.
• W2004037338 cites W1995115168 @default.
• W2004037338 cites W2003955264 @default.
• W2004037338 cites W2004278446 @default.
• W2004037338 cites W2055013229 @default.
• W2004037338 cites W2071705420 @default.
• W2004037338 cites W2077863736 @default.
• W2004037338 cites W2078400569 @default.
• W2004037338 cites W2079688281 @default.
• W2004037338 cites W2081365151 @default.
• W2004037338 cites W2081511916 @default.
• W2004037338 cites W2091926537 @default.
• W2004037338 cites W2097312459 @default.
• W2004037338 cites W2118263555 @default.
• W2004037338 cites W2120501943 @default.
• W2004037338 cites W2121263780 @default.
• W2004037338 cites W2127118734 @default.
• W2004037338 cites W2131422252 @default.
• W2004037338 cites W2137965829 @default.
• W2004037338 cites W2142284564 @default.
• W2004037338 cites W2143618467 @default.
• W2004037338 cites W2143877481 @default.
• W2004037338 cites W2146391441 @default.
• W2004037338 cites W2161938729 @default.
• W2004037338 cites W2163148645 @default.
• W2004037338 cites W2163773009 @default.
• W2004037338 cites W2258563421 @default.
• W2004037338 cites W4210898159 @default.
• W2004037338 doi "https://doi.org/10.1038/onc.2010.103" @default.
• W2004037338 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2880659" @default.
• W2004037338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20383201" @default.
• W2004037338 hasPublicationYear "2010" @default.
• W2004037338 type Work @default.
• W2004037338 sameAs 2004037338 @default.
• W2004037338 citedByCount "96" @default.
• W2004037338 countsByYear W20040373382012 @default.
• W2004037338 countsByYear W20040373382013 @default.
• W2004037338 countsByYear W20040373382014 @default.
• W2004037338 countsByYear W20040373382015 @default.
• W2004037338 countsByYear W20040373382016 @default.
• W2004037338 countsByYear W20040373382018 @default.
• W2004037338 countsByYear W20040373382019 @default.
• W2004037338 countsByYear W20040373382020 @default.
• W2004037338 countsByYear W20040373382021 @default.
• W2004037338 countsByYear W20040373382022 @default.
• W2004037338 countsByYear W20040373382023 @default.
• W2004037338 crossrefType "journal-article" @default.
• W2004037338 hasAuthorship W2004037338A5009183121 @default.
• W2004037338 hasAuthorship W2004037338A5009574665 @default.
• W2004037338 hasAuthorship W2004037338A5011907185 @default.
• W2004037338 hasAuthorship W2004037338A5039624947 @default.
• W2004037338 hasAuthorship W2004037338A5049715475 @default.
• W2004037338 hasAuthorship W2004037338A5089350105 @default.
• W2004037338 hasBestOaLocation W20040373382 @default.
• W2004037338 hasConcept C108636557 @default.
• W2004037338 hasConcept C11960822 @default.
• W2004037338 hasConcept C121608353 @default.
• W2004037338 hasConcept C134018914 @default.
• W2004037338 hasConcept C185323287 @default.
• W2004037338 hasConcept C2776235491 @default.
• W2004037338 hasConcept C2777553839 @default.
• W2004037338 hasConcept C2779536868 @default.
• W2004037338 hasConcept C2779723316 @default.
• W2004037338 hasConcept C42362537 @default.
• W2004037338 hasConcept C502942594 @default.
• W2004037338 hasConcept C54355233 @default.
• W2004037338 hasConcept C62478195 @default.
• W2004037338 hasConcept C86803240 @default.
• W2004037338 hasConcept C95444343 @default.
• W2004037338 hasConceptScore W2004037338C108636557 @default.
• W2004037338 hasConceptScore W2004037338C11960822 @default.
• W2004037338 hasConceptScore W2004037338C121608353 @default.
• W2004037338 hasConceptScore W2004037338C134018914 @default.
• W2004037338 hasConceptScore W2004037338C185323287 @default.
• W2004037338 hasConceptScore W2004037338C2776235491 @default.
• W2004037338 hasConceptScore W2004037338C2777553839 @default.
• W2004037338 hasConceptScore W2004037338C2779536868 @default.
• W2004037338 hasConceptScore W2004037338C2779723316 @default.
• W2004037338 hasConceptScore W2004037338C42362537 @default.
• W2004037338 hasConceptScore W2004037338C502942594 @default.
• W2004037338 hasConceptScore W2004037338C54355233 @default.
• W2004037338 hasConceptScore W2004037338C62478195 @default.

• next